Arcutis Biotherapeutics, Inc. was one of the few NDA holders celebrating a win in July, thanks to the US Food and Drug Administration’s approval of the company’s Zoryve as the first phosphodiesterase-4 inhibitor in a topical cream formulation.
ObsEva SA and the partnership of Medexus Pharmaceuticals, Inc. and medac GmbH were not so lucky. Notification...





